Selection of combination adjuvants for enhanced immunogenicity of a recombinant CelTOS vaccine against Plasmodium falciparum
Recently, there has been significant interest in developing combination adjuvants to achieve efficient vaccines. However, it remains uncertain which combinations of adjuvants could best enhance the immune response to the recombinant antigen. In the current study, to improve the immunogenicity of Pla...
Gespeichert in:
Veröffentlicht in: | Biochemical and biophysical research communications 2025-02, Vol.748, p.151310, Article 151310 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | 151310 |
container_title | Biochemical and biophysical research communications |
container_volume | 748 |
creator | Pirahmadi, Sakineh Zargar, Mostafa Pourhashem, Zeinab Vand-Rajabpour, Hediyeh Sani, Jafar J. Yousefi, Hemn Afzali, Shima Zakeri, Sedigheh Mehrizi, Akram Abouie |
description | Recently, there has been significant interest in developing combination adjuvants to achieve efficient vaccines. However, it remains uncertain which combinations of adjuvants could best enhance the immune response to the recombinant antigen. In the current study, to improve the immunogenicity of Plasmodium falciparum cell traversal protein for ookinetes and sporozoites (PfCelTOS), we tested three different adjuvants: MPL, Poly I:C, and QS-21 alone or in a triple mixture (MPL/Poly I:C/QS-21; MPQ) and a dual mixture (Poly I:C/QS-21; PQ).
BALB/c mice were immunized with recombinant PfCelTOS, either alone or combined with MPL, Poly I:C, QS-21, or with dual and triple adjuvant mixtures. Humoral and cellular immune responses were assessed in the various mouse groups, along with the functional activity of anti-PfCelTOS antibodies in oocyst inhibition.
The results showed that administering the PfCelTOS antigen with triple or dual adjuvant mixtures significantly increased specific antibody levels, as well as IFN-ɣ and TNF cytokine production (P 0.05).
The findings indicate that the dual mixture of Poly I:C and QS-21 is the most effective formulation for a vaccine against PfCelTOS. This discovery has important cost and safety implications by minimizing the adjuvants required to achieve an optimal immune response.
•Combination adjuvants enhance the immunogenicity of recombinant malaria vaccine.•Specific combination adjuvants should be evaluated with recombinant antigen.•Two different adjuvant mixtures (MPQ & PQ) were tested in combination with PfCelTOS.•Both adjuvant mixtures increased transmission-reducing activity in SMFA assay.•Dual adjuvant mixture (PQ) is an effective adjuvant for vaccine against PfCelTOS. |
doi_str_mv | 10.1016/j.bbrc.2025.151310 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3155720100</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006291X25000245</els_id><sourcerecordid>3155720100</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1526-ca6349fe84ca2c48935f12a481cd9b6ba805cb0d709b4313d01daef6cdc2e4c73</originalsourceid><addsrcrecordid>eNp9kE1r3DAQhkVpaDZp_0APRcdevJ2RP9aGXsqSJoVACkmgNyGPxqkWW9pK9kKgP752dttjT8ML7_PCPEK8R1gjYPVpt27bSGsFqlxjiTnCK7FCaCBTCMVrsQKAKlMN_jgXFyntABCLqnkjzvOmhgbzaiV-33PPNLrgZegkhaF13rxEY3fTwfgxyS5Eyf6n8cRWumGYfHhi78iNzwtkZOQT6Ee55f7h7l4eDJHzLM2TcT6N8ntv0hCsmwbZmZ7c3sRpeCvO5pD43eleisevVw_bm-z27vrb9sttRliqKiNT5UXTcV2QUVTUTV52qExRI9mmrVpTQ0kt2A00bZFjbgGt4a4iS4oL2uSX4uNxdx_Dr4nTqAeXiPveeA5T0jmW5UYBAsxVdaxSDClF7vQ-usHEZ42gF-t6pxfrerGuj9Zn6MNpf2oHtv-Qv5rnwudjgecvD46jTuR48elmd6O2wf1v_w_BNJWk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3155720100</pqid></control><display><type>article</type><title>Selection of combination adjuvants for enhanced immunogenicity of a recombinant CelTOS vaccine against Plasmodium falciparum</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Pirahmadi, Sakineh ; Zargar, Mostafa ; Pourhashem, Zeinab ; Vand-Rajabpour, Hediyeh ; Sani, Jafar J. ; Yousefi, Hemn ; Afzali, Shima ; Zakeri, Sedigheh ; Mehrizi, Akram Abouie</creator><creatorcontrib>Pirahmadi, Sakineh ; Zargar, Mostafa ; Pourhashem, Zeinab ; Vand-Rajabpour, Hediyeh ; Sani, Jafar J. ; Yousefi, Hemn ; Afzali, Shima ; Zakeri, Sedigheh ; Mehrizi, Akram Abouie</creatorcontrib><description>Recently, there has been significant interest in developing combination adjuvants to achieve efficient vaccines. However, it remains uncertain which combinations of adjuvants could best enhance the immune response to the recombinant antigen. In the current study, to improve the immunogenicity of Plasmodium falciparum cell traversal protein for ookinetes and sporozoites (PfCelTOS), we tested three different adjuvants: MPL, Poly I:C, and QS-21 alone or in a triple mixture (MPL/Poly I:C/QS-21; MPQ) and a dual mixture (Poly I:C/QS-21; PQ).
BALB/c mice were immunized with recombinant PfCelTOS, either alone or combined with MPL, Poly I:C, QS-21, or with dual and triple adjuvant mixtures. Humoral and cellular immune responses were assessed in the various mouse groups, along with the functional activity of anti-PfCelTOS antibodies in oocyst inhibition.
The results showed that administering the PfCelTOS antigen with triple or dual adjuvant mixtures significantly increased specific antibody levels, as well as IFN-ɣ and TNF cytokine production (P < 0.05), compared to PfCelTOS alone or combined with single adjuvants. These vaccine adjuvant mixtures also enhanced transmission-reducing activity (TRA), resulting in 76%–84% reductions in oocyst intensity in functional assays. Interestingly, comparable antibody levels and functional inhibitory activity were observed in the groups that received antigen with both dual and triple adjuvants (P > 0.05).
The findings indicate that the dual mixture of Poly I:C and QS-21 is the most effective formulation for a vaccine against PfCelTOS. This discovery has important cost and safety implications by minimizing the adjuvants required to achieve an optimal immune response.
•Combination adjuvants enhance the immunogenicity of recombinant malaria vaccine.•Specific combination adjuvants should be evaluated with recombinant antigen.•Two different adjuvant mixtures (MPQ & PQ) were tested in combination with PfCelTOS.•Both adjuvant mixtures increased transmission-reducing activity in SMFA assay.•Dual adjuvant mixture (PQ) is an effective adjuvant for vaccine against PfCelTOS.</description><identifier>ISSN: 0006-291X</identifier><identifier>ISSN: 1090-2104</identifier><identifier>EISSN: 1090-2104</identifier><identifier>DOI: 10.1016/j.bbrc.2025.151310</identifier><identifier>PMID: 39809136</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject><![CDATA[Adjuvants, Immunologic - administration & dosage ; Adjuvants, Immunologic - pharmacology ; Adjuvants, Vaccine - pharmacology ; Animals ; Antibodies, Protozoan - immunology ; Combination adjuvant ; Female ; Immunogenicity, Vaccine ; Lipid A - administration & dosage ; Lipid A - analogs & derivatives ; Lipid A - immunology ; Lipid A - pharmacology ; Malaria vaccine ; Malaria Vaccines - administration & dosage ; Malaria Vaccines - immunology ; Malaria, Falciparum - immunology ; Malaria, Falciparum - prevention & control ; Mice ; Mice, Inbred BALB C ; PfCelTOS ; Plasmodium falciparum - immunology ; Poly I-C - administration & dosage ; Poly I-C - immunology ; Poly I-C - pharmacology ; Protozoan Proteins - immunology ; Saponins - immunology ; Saponins - pharmacology ; TLR agonist ; Transmission blocking vaccine ; Vaccines, Synthetic - administration & dosage ; Vaccines, Synthetic - immunology]]></subject><ispartof>Biochemical and biophysical research communications, 2025-02, Vol.748, p.151310, Article 151310</ispartof><rights>2025 Elsevier Inc.</rights><rights>Copyright © 2025 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1526-ca6349fe84ca2c48935f12a481cd9b6ba805cb0d709b4313d01daef6cdc2e4c73</cites><orcidid>0000-0001-9502-0407</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0006291X25000245$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39809136$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pirahmadi, Sakineh</creatorcontrib><creatorcontrib>Zargar, Mostafa</creatorcontrib><creatorcontrib>Pourhashem, Zeinab</creatorcontrib><creatorcontrib>Vand-Rajabpour, Hediyeh</creatorcontrib><creatorcontrib>Sani, Jafar J.</creatorcontrib><creatorcontrib>Yousefi, Hemn</creatorcontrib><creatorcontrib>Afzali, Shima</creatorcontrib><creatorcontrib>Zakeri, Sedigheh</creatorcontrib><creatorcontrib>Mehrizi, Akram Abouie</creatorcontrib><title>Selection of combination adjuvants for enhanced immunogenicity of a recombinant CelTOS vaccine against Plasmodium falciparum</title><title>Biochemical and biophysical research communications</title><addtitle>Biochem Biophys Res Commun</addtitle><description>Recently, there has been significant interest in developing combination adjuvants to achieve efficient vaccines. However, it remains uncertain which combinations of adjuvants could best enhance the immune response to the recombinant antigen. In the current study, to improve the immunogenicity of Plasmodium falciparum cell traversal protein for ookinetes and sporozoites (PfCelTOS), we tested three different adjuvants: MPL, Poly I:C, and QS-21 alone or in a triple mixture (MPL/Poly I:C/QS-21; MPQ) and a dual mixture (Poly I:C/QS-21; PQ).
BALB/c mice were immunized with recombinant PfCelTOS, either alone or combined with MPL, Poly I:C, QS-21, or with dual and triple adjuvant mixtures. Humoral and cellular immune responses were assessed in the various mouse groups, along with the functional activity of anti-PfCelTOS antibodies in oocyst inhibition.
The results showed that administering the PfCelTOS antigen with triple or dual adjuvant mixtures significantly increased specific antibody levels, as well as IFN-ɣ and TNF cytokine production (P < 0.05), compared to PfCelTOS alone or combined with single adjuvants. These vaccine adjuvant mixtures also enhanced transmission-reducing activity (TRA), resulting in 76%–84% reductions in oocyst intensity in functional assays. Interestingly, comparable antibody levels and functional inhibitory activity were observed in the groups that received antigen with both dual and triple adjuvants (P > 0.05).
The findings indicate that the dual mixture of Poly I:C and QS-21 is the most effective formulation for a vaccine against PfCelTOS. This discovery has important cost and safety implications by minimizing the adjuvants required to achieve an optimal immune response.
•Combination adjuvants enhance the immunogenicity of recombinant malaria vaccine.•Specific combination adjuvants should be evaluated with recombinant antigen.•Two different adjuvant mixtures (MPQ & PQ) were tested in combination with PfCelTOS.•Both adjuvant mixtures increased transmission-reducing activity in SMFA assay.•Dual adjuvant mixture (PQ) is an effective adjuvant for vaccine against PfCelTOS.</description><subject>Adjuvants, Immunologic - administration & dosage</subject><subject>Adjuvants, Immunologic - pharmacology</subject><subject>Adjuvants, Vaccine - pharmacology</subject><subject>Animals</subject><subject>Antibodies, Protozoan - immunology</subject><subject>Combination adjuvant</subject><subject>Female</subject><subject>Immunogenicity, Vaccine</subject><subject>Lipid A - administration & dosage</subject><subject>Lipid A - analogs & derivatives</subject><subject>Lipid A - immunology</subject><subject>Lipid A - pharmacology</subject><subject>Malaria vaccine</subject><subject>Malaria Vaccines - administration & dosage</subject><subject>Malaria Vaccines - immunology</subject><subject>Malaria, Falciparum - immunology</subject><subject>Malaria, Falciparum - prevention & control</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>PfCelTOS</subject><subject>Plasmodium falciparum - immunology</subject><subject>Poly I-C - administration & dosage</subject><subject>Poly I-C - immunology</subject><subject>Poly I-C - pharmacology</subject><subject>Protozoan Proteins - immunology</subject><subject>Saponins - immunology</subject><subject>Saponins - pharmacology</subject><subject>TLR agonist</subject><subject>Transmission blocking vaccine</subject><subject>Vaccines, Synthetic - administration & dosage</subject><subject>Vaccines, Synthetic - immunology</subject><issn>0006-291X</issn><issn>1090-2104</issn><issn>1090-2104</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1r3DAQhkVpaDZp_0APRcdevJ2RP9aGXsqSJoVACkmgNyGPxqkWW9pK9kKgP752dttjT8ML7_PCPEK8R1gjYPVpt27bSGsFqlxjiTnCK7FCaCBTCMVrsQKAKlMN_jgXFyntABCLqnkjzvOmhgbzaiV-33PPNLrgZegkhaF13rxEY3fTwfgxyS5Eyf6n8cRWumGYfHhi78iNzwtkZOQT6Ee55f7h7l4eDJHzLM2TcT6N8ntv0hCsmwbZmZ7c3sRpeCvO5pD43eleisevVw_bm-z27vrb9sttRliqKiNT5UXTcV2QUVTUTV52qExRI9mmrVpTQ0kt2A00bZFjbgGt4a4iS4oL2uSX4uNxdx_Dr4nTqAeXiPveeA5T0jmW5UYBAsxVdaxSDClF7vQ-usHEZ42gF-t6pxfrerGuj9Zn6MNpf2oHtv-Qv5rnwudjgecvD46jTuR48elmd6O2wf1v_w_BNJWk</recordid><startdate>20250208</startdate><enddate>20250208</enddate><creator>Pirahmadi, Sakineh</creator><creator>Zargar, Mostafa</creator><creator>Pourhashem, Zeinab</creator><creator>Vand-Rajabpour, Hediyeh</creator><creator>Sani, Jafar J.</creator><creator>Yousefi, Hemn</creator><creator>Afzali, Shima</creator><creator>Zakeri, Sedigheh</creator><creator>Mehrizi, Akram Abouie</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9502-0407</orcidid></search><sort><creationdate>20250208</creationdate><title>Selection of combination adjuvants for enhanced immunogenicity of a recombinant CelTOS vaccine against Plasmodium falciparum</title><author>Pirahmadi, Sakineh ; Zargar, Mostafa ; Pourhashem, Zeinab ; Vand-Rajabpour, Hediyeh ; Sani, Jafar J. ; Yousefi, Hemn ; Afzali, Shima ; Zakeri, Sedigheh ; Mehrizi, Akram Abouie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1526-ca6349fe84ca2c48935f12a481cd9b6ba805cb0d709b4313d01daef6cdc2e4c73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Adjuvants, Immunologic - administration & dosage</topic><topic>Adjuvants, Immunologic - pharmacology</topic><topic>Adjuvants, Vaccine - pharmacology</topic><topic>Animals</topic><topic>Antibodies, Protozoan - immunology</topic><topic>Combination adjuvant</topic><topic>Female</topic><topic>Immunogenicity, Vaccine</topic><topic>Lipid A - administration & dosage</topic><topic>Lipid A - analogs & derivatives</topic><topic>Lipid A - immunology</topic><topic>Lipid A - pharmacology</topic><topic>Malaria vaccine</topic><topic>Malaria Vaccines - administration & dosage</topic><topic>Malaria Vaccines - immunology</topic><topic>Malaria, Falciparum - immunology</topic><topic>Malaria, Falciparum - prevention & control</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>PfCelTOS</topic><topic>Plasmodium falciparum - immunology</topic><topic>Poly I-C - administration & dosage</topic><topic>Poly I-C - immunology</topic><topic>Poly I-C - pharmacology</topic><topic>Protozoan Proteins - immunology</topic><topic>Saponins - immunology</topic><topic>Saponins - pharmacology</topic><topic>TLR agonist</topic><topic>Transmission blocking vaccine</topic><topic>Vaccines, Synthetic - administration & dosage</topic><topic>Vaccines, Synthetic - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pirahmadi, Sakineh</creatorcontrib><creatorcontrib>Zargar, Mostafa</creatorcontrib><creatorcontrib>Pourhashem, Zeinab</creatorcontrib><creatorcontrib>Vand-Rajabpour, Hediyeh</creatorcontrib><creatorcontrib>Sani, Jafar J.</creatorcontrib><creatorcontrib>Yousefi, Hemn</creatorcontrib><creatorcontrib>Afzali, Shima</creatorcontrib><creatorcontrib>Zakeri, Sedigheh</creatorcontrib><creatorcontrib>Mehrizi, Akram Abouie</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biochemical and biophysical research communications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pirahmadi, Sakineh</au><au>Zargar, Mostafa</au><au>Pourhashem, Zeinab</au><au>Vand-Rajabpour, Hediyeh</au><au>Sani, Jafar J.</au><au>Yousefi, Hemn</au><au>Afzali, Shima</au><au>Zakeri, Sedigheh</au><au>Mehrizi, Akram Abouie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Selection of combination adjuvants for enhanced immunogenicity of a recombinant CelTOS vaccine against Plasmodium falciparum</atitle><jtitle>Biochemical and biophysical research communications</jtitle><addtitle>Biochem Biophys Res Commun</addtitle><date>2025-02-08</date><risdate>2025</risdate><volume>748</volume><spage>151310</spage><pages>151310-</pages><artnum>151310</artnum><issn>0006-291X</issn><issn>1090-2104</issn><eissn>1090-2104</eissn><abstract>Recently, there has been significant interest in developing combination adjuvants to achieve efficient vaccines. However, it remains uncertain which combinations of adjuvants could best enhance the immune response to the recombinant antigen. In the current study, to improve the immunogenicity of Plasmodium falciparum cell traversal protein for ookinetes and sporozoites (PfCelTOS), we tested three different adjuvants: MPL, Poly I:C, and QS-21 alone or in a triple mixture (MPL/Poly I:C/QS-21; MPQ) and a dual mixture (Poly I:C/QS-21; PQ).
BALB/c mice were immunized with recombinant PfCelTOS, either alone or combined with MPL, Poly I:C, QS-21, or with dual and triple adjuvant mixtures. Humoral and cellular immune responses were assessed in the various mouse groups, along with the functional activity of anti-PfCelTOS antibodies in oocyst inhibition.
The results showed that administering the PfCelTOS antigen with triple or dual adjuvant mixtures significantly increased specific antibody levels, as well as IFN-ɣ and TNF cytokine production (P < 0.05), compared to PfCelTOS alone or combined with single adjuvants. These vaccine adjuvant mixtures also enhanced transmission-reducing activity (TRA), resulting in 76%–84% reductions in oocyst intensity in functional assays. Interestingly, comparable antibody levels and functional inhibitory activity were observed in the groups that received antigen with both dual and triple adjuvants (P > 0.05).
The findings indicate that the dual mixture of Poly I:C and QS-21 is the most effective formulation for a vaccine against PfCelTOS. This discovery has important cost and safety implications by minimizing the adjuvants required to achieve an optimal immune response.
•Combination adjuvants enhance the immunogenicity of recombinant malaria vaccine.•Specific combination adjuvants should be evaluated with recombinant antigen.•Two different adjuvant mixtures (MPQ & PQ) were tested in combination with PfCelTOS.•Both adjuvant mixtures increased transmission-reducing activity in SMFA assay.•Dual adjuvant mixture (PQ) is an effective adjuvant for vaccine against PfCelTOS.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>39809136</pmid><doi>10.1016/j.bbrc.2025.151310</doi><orcidid>https://orcid.org/0000-0001-9502-0407</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0006-291X |
ispartof | Biochemical and biophysical research communications, 2025-02, Vol.748, p.151310, Article 151310 |
issn | 0006-291X 1090-2104 1090-2104 |
language | eng |
recordid | cdi_proquest_miscellaneous_3155720100 |
source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
subjects | Adjuvants, Immunologic - administration & dosage Adjuvants, Immunologic - pharmacology Adjuvants, Vaccine - pharmacology Animals Antibodies, Protozoan - immunology Combination adjuvant Female Immunogenicity, Vaccine Lipid A - administration & dosage Lipid A - analogs & derivatives Lipid A - immunology Lipid A - pharmacology Malaria vaccine Malaria Vaccines - administration & dosage Malaria Vaccines - immunology Malaria, Falciparum - immunology Malaria, Falciparum - prevention & control Mice Mice, Inbred BALB C PfCelTOS Plasmodium falciparum - immunology Poly I-C - administration & dosage Poly I-C - immunology Poly I-C - pharmacology Protozoan Proteins - immunology Saponins - immunology Saponins - pharmacology TLR agonist Transmission blocking vaccine Vaccines, Synthetic - administration & dosage Vaccines, Synthetic - immunology |
title | Selection of combination adjuvants for enhanced immunogenicity of a recombinant CelTOS vaccine against Plasmodium falciparum |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T01%3A27%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Selection%20of%20combination%20adjuvants%20for%20enhanced%20immunogenicity%20of%20a%20recombinant%20CelTOS%20vaccine%20against%20Plasmodium%20falciparum&rft.jtitle=Biochemical%20and%20biophysical%20research%20communications&rft.au=Pirahmadi,%20Sakineh&rft.date=2025-02-08&rft.volume=748&rft.spage=151310&rft.pages=151310-&rft.artnum=151310&rft.issn=0006-291X&rft.eissn=1090-2104&rft_id=info:doi/10.1016/j.bbrc.2025.151310&rft_dat=%3Cproquest_cross%3E3155720100%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3155720100&rft_id=info:pmid/39809136&rft_els_id=S0006291X25000245&rfr_iscdi=true |